Philippines
Tuberculosis profile
| High TB burden | High MDR-TB burden |
Population  2013 98 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 27 (25–29) 27 (25–29)
Mortality (HIV+TB only) 0.058 (0.042–0.077) 0.06 (0.04–0.08)
Prevalence  (includes HIV+TB) 430 (380–490) 438 (385–495)
Incidence  (includes HIV+TB) 290 (260–330) 292 (261–331)
Incidence (HIV+TB only) 0.31 (0.18–0.34) 0.32 (0.18–0.35)
Case detection, all forms (%) 80 (71–90)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 2 (1.4–2.7) 21 (16–29)
MDR-TB cases among notified pulmonary
TB cases
4 400 (3 100–6 000) 4 100 (3 000–5 500)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 97 353   4 669
Pulmonary, clinically diagnosed 123 510   0
Extrapulmonary 4 386   0
       
Total new and relapse 229 918    
Previously treated, excluding relapses 14 474    
Total cases notified 244 392    
Among 97 221 new cases:
2 065 (2%) cases aged under 15 years; male:female ratio: 2.3
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 3 137 (3%) 13 419 (70%) 17 241
Laboratory-confirmed RR-/MDR-TB cases     3 962
Patients started on MDR-TB treatment     2 262
TB/HIV 2013 Number (%)
TB patients with known HIV status 5 034 (2)
HIV-positive TB patients 26 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB 3 006  
HIV-positive people provided with IPT    
Treatment success rate (%)
New cases registered in 2012 88
Previously treated cases registered in 2012  
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 41
XDR-TB cases started on second-line treatment in 2011 67
Laboratories 2013  
Smear (per 100 000 population) 2.6
Culture (per 5 million population) 0.9
Drug susceptibility testing (per 5 million population) 0.2
Sites performing Xpert MTB/RIF 16
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 117
% Funded domestically 27%
% Funded internationally 25%
% Unfunded 48%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-08-05 Data: www.who.int/tb/data